ASCENT PHARMS INC is a generic drug manufacturer focused on Oncology, Neurology, Metabolic.
ASCENT PHARMS INC's Key Drugs
ASCENT PHARMS INC's core commercial portfolio centers on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, IBUPROFEN AND FAMOTIDINE, spanning Oncology and Neurology — its most strategically important drugs approved in the last 15 years.
ASCENT PHARMS INC's Recent FDA Approvals
ASCENT PHARMS INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
ASCENT PHARMS INC's Therapeutic Areas
ASCENT PHARMS INC's approved drugs and pipeline span 4 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ASCENT PHARMS INC's Top Competitors
ASCENT PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and AZURITY. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ASCENT PHARMS INC Pipeline Snapshot
Active clinical trials for ASCENT PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2015-09-22
- Latest
- 2026-06-18
- Applications
- 54